



FOR IMMEDIATE RELEASE:

**OSTEOGENEX ANNOUNCES ISSUANCE OF A U.S. PATENT COVERING
ANTI-SCLEROSTIN BISPHOSPHONATE COMBINATION THERAPY**

(Kansas City, KS, 1st June 2012) – OsteoGeneX, a Kansas City, Kansas-based pharmaceutical company, is focused on commercializing orally administered bone building therapies directed against the target Sclerostin for chronic and acute bone disorders.

OsteoGeneX announced today that the U.S. Patent and Trademark Office has issued its patent number 8,178,099 titled “Methods of Altering Bone Growth by Administration of Sost or Wise Antagonist or Agonist” with claims covering the use of anti-sclerostin antibodies in combination with bisphosphonates to treat systemic bone density loss, i.e. osteoporosis.

This patent raises OsteoGeneX’s patent portfolio to three issued patents. The current portfolio contains 16 filed U.S. patent applications and 15 PCT patent applications. OsteoGeneX is currently inviting interested licensees to view its patent portfolio.

“This patent issuance for OGX is another important milestone as we continue to build and solidify intellectual property protection for our entire product portfolio” said Dr. Debra Ellies, CEO and President of OsteoGeneX.

About OsteoGeneX

OsteoGeneX is committed to leveraging its innovative signaling pathway technologies to discover and develop small molecule therapeutics that are focused primarily on building new bone. OsteoGeneX was founded to take advantage of its unique insight on the Sclerostin/Wise (Ectodin, Usag-1, SostDC) family. OsteoGeneX utilizes a novel approach to modulate the activity of Sclerostin/Wise that ultimately controls the growth of bone. The company is establishing itself as the premier company in this field with its lead platform program in osteoporosis, small molecule anabolic bone therapeutics in preclinical development for the treatment of bone loss.

CONTACT:

Kerri Dean
(913) 945-6763
kerri@osteogenex.com

Debra L. Ellies, Ph.D.
(913) 945-6763
debs@osteogenex.com

###